|
rs2228570
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The VDR polymorphism FokI (rs2228570) seems to increase the risk of ovarian cancer.
|
29113037 |
2017 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cumulative risk analysis revealed 3 unfavorable variants that increased significantly the risk of developing ovarian cancer (p.Ile1145 = ABCB1+ p.Asp1853Asn ATM+ p.Ser406Ala ATP7B- OR 7,47; p = 0,002) and significantly modified the progression free survival (PFS) of the patients, and also two favorable genotypes which protected against ovarian cancer (p.Arg952Lys ATP7B+ p.Arg72Pro TP53- OR 0,50; p = 0,008).
|
25591549 |
2015 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion SNPs in WRAP53 (rs2287497 and rs2287498) have stronger association with an ovarian cancer risk than rs1042522 in TP53.
|
23192612 |
2013 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
|
21952824 |
2012 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The rs1042522 polymorphism was not overall associated with o</span>varian cancer risk.
|
25060098 |
2014 |
|
rs144848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
There was no association between BRCA2 N372H and risk of borderline or invasive epithelial ovarian cancer.
|
14555511 |
2003 |
|
rs144848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The HH genotype of the nonconservative amino acid substitution polymorphism N37</span>2H in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and ovarian cancer.
|
15668505 |
2005 |
|
rs144848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Moreover, stratified analyses by the cancer type and source of control observed significantly increased risk associated with BRCA2 N372H in subgroups with ovarian cancer, non-Hodgkin lymphoma and population-based controls, but not breast cancer or hospital-based controls.
|
25348552 |
2014 |
|
rs144848
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The subgroup analysis for serous cancer subgroup showed that the significant association could be detected under recessive model (OR = 1.38, 95% CI, 1.01-1.89, P = 0.04) and under homozygote comparison (OR = 1.46, 95% CI, 1.06-2.01, P = 0.022).Our meta-analysis suggests that the N372H polymorphism is associated with susceptibility of ovarian cancer.
|
26496279 |
2015 |
|
rs1799950
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Further characterisation of rs1799950 is now warranted in relation to chemosensitivity and susceptibility to developing ovarian carcinoma.
|
29298688 |
2018 |
|
rs1799950
|
|
|
0.040 |
GeneticVariation |
BEFREE |
No association was detected between EOC risk and BRCA1 Q356R, BRCA1 P871L, RAD51 g135c, RAD51 g172t, RAD52 c2259t, NBS1 L34L, NBS1 E185Q, NBS1 A399A, NBS1 P672P, XRCC2 g4324c, XRCC2 c41657t and XRCC3 T241M.
|
15924337 |
2005 |
|
rs1799950
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The rare form of the Q356R polymorphism was significantly ( P = 0.03) associated with a family history of ovarian cancer, suggesting that this polymorphism may influence ovarian cancer risk.
|
10196379 |
1999 |
|
rs1799950
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We resequenced BRCA1 and BRCA2 in 194 women with a familial history of breast and/or ovarian cancer and identified nine possibly biologically relevant polymorphisms (BRCA1 Gln356Arg, Pro871Leu, Glu1038Gly, Ser1613Gly, and Met1652Ile.
|
19661094 |
2009 |
|
rs397507444
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion, the results of this meta-analysis indicate that the MTHFR C677T and A1298C polymorphisms are not associated with ovarian cancer risk, especially in Caucasians.
|
22810649 |
2012 |
|
rs397507444
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis suggests that the A1298C polymorphism in the MTHFR gene may be not associated with susceptibility to ovarian cancer.
|
26345746 |
2015 |
|
rs397507444
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In addition, there is no association between A1298C gene polymorphism and ovarian cancer, including Caucasian and Asian women.
|
24720627 |
2014 |
|
rs397507444
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Overall, we observed no association between either SNP and ovarian cancer risk (pooled C677T p(trend)=0.59 and A1298C p(</span>trend)=0.58).
|
20817226 |
2010 |
|
rs1042838
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Five haplotypes occurred with greater than 5% frequency, and the haplotype carrying the V</span>660L variant had a significant association with ovarian cancer (odds ratio = 0.76, 95% confidence interval: 0.62, 0.92).
|
15718480 |
2005 |
|
rs1042838
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This meta-analysis suggests that the two polymorphisms of PGR, Alu insertion and Val660Leu, may contribute to ovarian cancer susceptibility as low-penetrance risk factors.
|
25228088 |
2015 |
|
rs1042838
|
|
|
0.030 |
GeneticVariation |
BEFREE |
No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer.
|
11323389 |
2001 |
|
rs1271572
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The recessive model of ESR2 rs1271572 and the dominant model of ESR2 rs3020450 might be susceptible factors for ovarian cancer.
|
29535531 |
2018 |
|
rs1271572
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Compared to homozygous common allele carriers, homozygous carriers of variant alleles for rs1271572 [odds ratio (OR) = 1.79, 95% confidence interval (CI):1.15-2.79, p global = 0.01] and rs1256030 [OR = 1.67, CI: 1.08-2.59, p global = 0.04], and women with haplotypes, including variant alleles of rs1271572, rs1256030, and rs1256031 SNPs [OR = 1.75, CI: 1.17-2.63, p global = 0.007], had significantly increased risk of ovarian carcinoma.
|
18704709 |
2009 |
|
rs1271572
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This pooled analysis suggests that rs1271572 might influence the risk of ovarian cancer, in particular among younger women.
|
21673961 |
2011 |
|
rs2032582
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy.
|
16467099 |
2006 |
|
rs2032582
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genetic polymorphisms such as ERCC1 8092C>A, ABCB1 2677G>T/A, GSTP1 I105V and GSTT1 polymorphisms may affect drug response, toxicity and survival in patient with EOC who received taxane- and platinum-based chemotherapy after surgery.
|
19203783 |
2009 |